US Molecular Diagnostics Transplant Market

ID: MRFR/MED/51800-HCR 200 Pages Nidhi Mandole Last Updated: September 17, 2026
US Molecular Diagnostics for Transplant Market Research Report By Product (Reagents & Kits, Instruments, Services & Software), By Technology (Polymerase Chain Reaction (PCR), Sequencing, Microarray, Others) and By End User (Hospitals and Transplant Centers, Research Laboratories & Academic Institutes, Others) -Forecast to 2035
US Molecular Diagnostics Transplant Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)8.08%
2024 Market Size$ 206.34 Million
2025 Market Size$ 224.71 Million
2035 Market Size$ 485.1 Million
Key Players
Thermo Fisher Scientific
Abbott Laboratories
Roche Diagnostics
Qiagen
Hologic
Illumina
Trends
  • Technological Advancements
  • Regulatory Support
  • Focus on Personalized Medicine
Opportunities
  • Focus on Personalized Medicine
  • Increased Awareness and Education
  • Rising Incidence of Chronic Diseases
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Application (USD Million)
      1. 4.1.1 Transplant Rejection Monitoring
      2. 4.1.2 Infectious Disease Testing
      3. 4.1.3 Donor-Recipient Matching
      4. 4.1.4 Post-Transplant Monitoring
    2. 4.2 Healthcare, BY Technology (USD Million)
      1. 4.2.1 Polymerase Chain Reaction
      2. 4.2.2 Next Generation Sequencing
      3. 4.2.3 Microarray Technology
      4. 4.2.4 In Situ Hybridization
    3. 4.3 Healthcare, BY End Use (USD Million)
      1. 4.3.1 Hospitals
      2. 4.3.2 Diagnostic Laboratories
      3. 4.3.3 Research Institutions
      4. 4.3.4 Transplant Centers
    4. 4.4 Healthcare, BY Sample Type (USD Million)
      1. 4.4.1 Blood
      2. 4.4.2 Tissue
      3. 4.4.3 Urine
      4. 4.4.4 Saliva
    5. 4.5 Healthcare, BY Test Type (USD Million)
      1. 4.5.1 Genetic Testing
      2. 4.5.2 Serological Testing
      3. 4.5.3 Molecular Testing
      4. 4.5.4 Cytogenetic Testing
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Thermo Fisher Scientific (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Abbott Laboratories (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Roche Diagnostics (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Qiagen (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Hologic (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Illumina (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Becton Dickinson (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Genomic Health (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Myriad Genetics (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY APPLICATION
    3. 6.3 US MARKET ANALYSIS BY TECHNOLOGY
    4. 6.4 US MARKET ANALYSIS BY END USE
    5. 6.5 US MARKET ANALYSIS BY SAMPLE TYPE
    6. 6.6 US MARKET ANALYSIS BY TEST TYPE
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
    15. 6.15 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
    17. 6.17 HEALTHCARE, BY END USE, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Million)
    19. 6.19 HEALTHCARE, BY SAMPLE TYPE, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY SAMPLE TYPE, 2024 TO 2035 (USD Million)
    21. 6.21 HEALTHCARE, BY TEST TYPE, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY TEST TYPE, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2026-2035 (USD Million)
      2. 7.2.2 BY TECHNOLOGY, 2026-2035 (USD Million)
      3. 7.2.3 BY END USE, 2026-2035 (USD Million)
      4. 7.2.4 BY SAMPLE TYPE, 2026-2035 (USD Million)
      5. 7.2.5 BY TEST TYPE, 2026-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Molecular Diagnostics Transplant Market Segmentation

US Molecular Diagnostics Transplant Market By Application (USD Million, 2026-2035)

  • Transplant Rejection Monitoring
  • Infectious Disease Testing
  • Donor-Recipient Matching
  • Post-Transplant Monitoring

US Molecular Diagnostics Transplant Market By US Molecular Diagnostics Transplant Market (USD Million, 2026-2035)

  • Polymerase Chain Reaction
  • Next Generation Sequencing
  • Microarray US Molecular Diagnostics Transplant Market
  • In Situ Hybridization

US Molecular Diagnostics Transplant Market By End Use (USD Million, 2026-2035)

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutions
  • Transplant Centers

US Molecular Diagnostics Transplant Market By Sample Type (USD Million, 2026-2035)

  • Blood
  • Tissue
  • Urine
  • Saliva

US Molecular Diagnostics Transplant Market By Test Type (USD Million, 2026-2035)

  • Genetic Testing
  • Serological Testing
  • Molecular Testing
  • Cytogenetic Testing

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.